help button home button Am J Pathol Epitomics
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marx, N.
Right arrow Articles by Plutzky, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marx, N.
Right arrow Articles by Plutzky, J.
(American Journal of Pathology. 1998;153:17-23.)
© 1998 American Society for Investigative Pathology


Short Communication

Macrophages in Human Atheroma Contain PPAR{gamma}

Differentiation-Dependent Peroxisomal Proliferator-ActivatedReceptor {gamma} (PPAR{gamma}) Expression and Reduction of MMP-9 Activitythrough PPAR{gamma} Activation in Mononuclear Phagocytes inVitro

Nikolaus Marx, Galina Sukhova, Curran Murphy, Peter Libby and Jorge Plutzky

From the Vascular Medicine and Atherosclerosis Unit, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Mononuclear phagocytes play an important role in atherosclerosis and its sequela plaque rupture in part by their secretion of matrix metalloproteinases (MMPs), including MMP-9. Peroxisomal proliferator-activated receptor {gamma} (PPAR{gamma}), a transcription factor in the nuclear receptor superfamily, regulates gene expression in response to various activators, including 15-deoxy-{Delta}12,14-prostaglandin J2 and the antidiabetic agent troglitazone. The role of PPAR{gamma} in human atherosclerosis is unexplored. We report here that monocytes/macrophages in human atherosclerotic lesions (n = 12) express immunostainable PPAR{gamma}. Normal artery specimens (n = 6) reveal minimal immunoreactive PPAR{gamma}. Human monocytes and monocyte-derived macrophages cultured for 6 days in 5% human serum expressed PPAR{gamma} mRNA and protein by reverse transcription-polymerase chain reaction and Western blotting, respectively. In addition, PPAR{gamma} mRNA expression in U937 cells increased during phorbol 12-myristate 13 acetate-induced differentiation. Stimulation of PPAR{gamma} with troglitazone or 15-deoxy-{Delta}12,14-prostaglandin J2 in human monocyte-derived macrophages inhibited MMP-9 gelatinolytic activity in a concentration-dependent fashion as revealed by zymography. This inhibition correlates with decreased MMP-9 secretion as determined by Western blotting. Thus, PPAR{gamma} is present in macrophages in human atherosclerotic lesions and may regulate expression and activity of MMP-9, an enzyme implicated in plaque rupture. PPAR{gamma} is likely to be an important regulator of monocyte/macrophage function with relevance for human atherosclerotic disease.



    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Macrophages influence many aspects of atherosclerosis, including the vulnerability of plaques to undergo disruption and thrombosis.1,2 Pathological studies have shown abundant macrophages in ruptured atheroma.3 In vitro biomechanical studies have shown that the fibrous cap of macrophage-rich plaques has reduced tensile strength.4 The role of macrophages in plaque rupture may involve secretion of matrix metalloproteinases (MMPs), enzymes that participate in extracellular matrix degradation.5,6 MMP-9, also referred to as gelatinase B, is the predominant MMP secreted by monocytes/macrophages in vitro.6-8 A number of inflammatory cytokines found in atheroma can augment MMP-9 expression by mononuclear phagocytes, including interleukin 1, tumor necrosis factor {alpha},9 and CD40 ligand.10 Nonetheless, the majority of atheroma are stable. This suggests that inhibitors of MMP-9 expression must be at work, opposing the effects of proinflammatory mediators in the plaque.

We therefore undertook an effort to identify endogenous inhibitors of MMP-9 expression. Work from other groups has established that activation of various nuclear hormone receptors can inhibit MMP expression through a variety of mechanisms.11 Interest is growing regarding the role of peroxisomal proliferation activator receptors (PPARs), a subgroup of the nuclear receptor superfamily, as transcriptional mediators.12,13 One of these, PPAR{gamma}, has been implicated as a "master regulator" of lipid metabolism and adipogenesis; ectopic overexpression of PPAR{gamma} in fibroblasts redirects these cells into an adipogenic program.14,15 Like other nuclear receptors, PPAR{gamma} contains a ligand binding domain and a central DNA binding domain, which interacts with PPAR response elements in the promoter of target genes.16 Specific activators identified thus far include both the naturally occurring prostaglandin D metabolite 15-deoxy-{Delta}12,14-prostaglandin J2 (15 d-PGJ2)17-19 and the synthetic antidiabetic agent troglitazone.20-22 The role of PPAR{gamma} in nonadipocytes has received little attention, although expression had been previously noted in hematopoietic cell lines.23 Recent work suggests PPAR{gamma} stimulation can inhibit both cytokine-induced activation of macrophages24 and in vitro expression of transfected promoter constructs of genes implicated in atherogenesis, including MMP-9.25

The present study tested the hypotheses 1) that macrophages in human atheroma express PPAR{gamma}, 2) that this novel nuclear receptor is regulated during differentiation of monocytes into macrophages, and 3) that PPAR{gamma} activation can limit MMP-9 expression and enzymatic activity by these cells.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Immunohistochemistry

Surgical specimens of human carotid atherosclerotic lesions were obtained by protocols approved by the Human Investigation Review Committee at Brigham and Women's Hospital. Serial cryostat sections (5 mm) were cut, air dried onto microscopic slides, and fixed in acetone at -20°C for 5 minutes. Staining for PPAR{gamma} was performed with a polyclonal rabbit anti-human PPAR{gamma} peptide antibody19 (a generous gift from Dr. Mitchell Lazar, University of Pennsylvania School of Medicine, Philadelphia). Macrophages were identified by staining with anti-CD68 antibody (DAKO, Carpinteria, CA). Sections were preincubated with PBS containing 0.3% hydrogen peroxidase activity and stained for 1 hour with primary antibody diluted in PBS supplemented with 5% appropriate serum. Negative control was performed by preabsorbing the anti-PPAR{gamma} antibodies with the peptide from which the antibody was derived and subsequently using these "peptide-blocked PPAR{gamma} antibodies" at concentrations similar to those of experimental conditions. Finally, sections were incubated with the respective biotinylated secondary antibody (Vector Laboratories, Burlingame, CA) followed by avidin-biotin-peroxidase complex (Vectastain ABC kit, Vector Laboratories). Antibody binding was visualized with 3-amino-9-ethyl carbazole (Vector Laboratories) or with True Blue Peroxidase substrate (Kirkegaard & Perry Laboratories, Gaithersburg, MD). Sections were counterstained with Gill's Hematoxylin or Contrast Red (Kirkegaard & Perry Laboratories). Computer-assisted image analysis was used to quantify staining on sections using Optimas 5.2 software. Percentage area of positive staining for PPAR{gamma} or CD68 in the shoulders of the plaques, defined as the intimal regions flanking the lipid core, was compared with the percentage area of positive staining in other zones of the sections.

Cell Culture

Human monocytes were isolated from peripheral blood of healthy volunteers by sequential gradient centrifugation with Lymphocyte Separation Medium (Organon Technika, Durham, NC) and One Step Monocytes (Accurate Chemical and Scientific Co., Westbury, NY). Monocytes were plated at a concentration of 3 x 109 cells/L in serum-free M199 medium (BioWhittaker, Walkersville, MD) and isolated by adherence to plastic dishes at 37°C. Nonadherent cells were washed three times with Hanks' buffer (Life Technologies, Gaithersburg, MD), and the remaining adherent cells were cultured in M199 medium with 5% human serum at 37°C/5%CO2. Medium was changed every 2 days for 6 days, and resulting cells were used as "monocyte-derived macrophages." In some experiments, monocytes were cultured for 6 days with 5% human serum in the absence or presence of PPAR{gamma} activators troglitazone (provided by Parke Davis (Morris Plains, NJ) and dissolved according to manufacturer's instructions) or 15 d-PGJ2 (CalbioChem, La Jolla, CA) at concentrations indicated. After 6 days, cells were changed to serum-free conditions, and supernatants were collected after 24 hours for further analysis. The human monocyte-like cell line U937, obtained from American Type Culture Collection (Manassas, VA), was cultured in RPMI 1640 medium (BioWhittaker) with 1% glutamine (Sigma Chemical Co., St. Louis, MO), 1% penicillin-streptomycin (Sigma) and 10% fetal calf serum.

RNA Extraction and Reverse Transcription-Polymerase Chain Reaction

Total RNA from 107 cells was isolated by the single-step guanidium thiocyanate-phenol-chloroform method using RNAzol from Tel-Test (Friendswood, TX). Two micrograms of total RNA was reverse-transcribed into cDNA with 1 U/ml reverse transcriptase (Superscript, Life Technologies) at 37°C for 1 hour in standard buffer. For the amplification of PPAR{gamma} cDNA, two oligonucleotide primers were designed from nucleotides +235 to 708 (a 473-bp fragment): sense primer, 5'-TCTCTCCGTAATGGAAGACC-3'; anti-sense primer, 5'-CCCCTACAGAGTATTACG-3'. The polymerase chain reaction reaction was carried out in a standard buffer (Life Technologies) with 200 ng of each primer (IDT, Coralville, CA), 33 mmol/L MgCl2, and 0.5 U Taq polymerase (Life Technologies) for 30 cycles. Polymerase chain reaction products (10 µl/25µl reaction) were analyzed on a 2% agarose gel.

Northern Blot Analysis

Five micrograms of total RNA from undifferentiated and phorbol 12-myristate 13-acetate (PMA)-differentiated U937 cells was subjected to electrophoresis on a 1.2% agarose gel and transferred using traditional Northern blotting techniques. The membranes were ultraviolet-crosslinked, prehybridized at 42°C (50% formamide, 5x Denhardt's solution, 5x standard saline citrate, 0.5% sodium dodecyl sulfate, and 20 mmol/L salmon sperm DNA), and hybridized in the same buffer with a random primed radiolabeled ([{alpha}-P32]dCTP) Sal-1 fragment of pCMX-PPAR{gamma} (generously provided by Dr. Bruce Spiegelman, Dana-Farber Cancer Institute, Boston, MA).14 The membranes were washed at 60°C in 1% sodium dodecyl sulfate/2x standard saline citrate and exposed (1–3 days, -70°C) to Kodak X-OMAT film with an intensifying screen.

Preparation of Nuclear and Cytosolic Extracts and Western Blot Analysis

For Western blot analysis, a positive control was generated by transiently transfecting a PPAR{gamma} expression construct, pCMX-PPAR{gamma},14 into human skin fibroblasts using lipofectamine (Life Technologies) according to the manufacturer's protocol. Nuclear and cytosolic extracts of 107 cells were prepared separately. Cells were lysed in 10 mmol/L Hepes (pH 7.9), 1.5 mmol/L MgCl2, 10 mmol/L KCl, and 0.5% Nonidet P-40. Nuclei were pelleted at 13,000 x g for 5 minutes, and the resulting supernatant was used as the cytosolic fraction. Nuclei were lysed in 20 mmol/L Hepes (pH 7.9), 1.5 mmol/L MgCl2, 420 mmol/L NaCl, and 0.2 mmol/L ethylenediaminetetraacetate. After centrifugation at 13,000 x g for 5 minutes, the supernatant was diluted in an equal volume of 20 mmol/L Hepes (pH 7.9), 100 mmol/L KCl, 0.2 mmol/L ethylenediaminetetraacetate, and 20% glycerol and used as nuclear extract. Protein concentration of nuclear and cystolic extracts was determined using a protein assay (Pierce, Rockford, IL). Processed samples were applied to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels, and protein was transferred to nitrocellulose membranes (Millipore, Bedford, MA) using semidry blotting for 1 hour, as described previously.10

Membranes were blocked overnight in Tris-buffered saline-Tween with 5% dry milk and incubated with goat anti-human PPAR{gamma} monoclonal antibodies (N-20, Santa Cruz Biotechnology, San Diego, CA) for 1 hour. After washing, membranes were stained with horseradish-conjugated rabbit anti-goat monoclonal antibodies. Antigen detection was performed with a chemiluminescent detection system (NEN, Boston, MA). Similar methods were used to perform Western blots on MMP-9 in monocyte-derived macrophage supernatants using a specific rabbit anti-human MMP-9 antibody (Oncogene Science, Cambridge, MA).

Substrate Gel Zymography

Gelatinolytic activity of MMP-9 from conditioned medium (10 µl/500 µl total supernatant loaded) of monocytes or monocyte-derived macrophages was analyzed by zymography on gelatin-containing polyacrylamide.10 Equal amounts were loaded in each lane. After washing in 2.5% Triton X-100, gels were incubated overnight at 37°C in 50 mmol/L Tris-HCl (pH 7.4) containing CaCl2 and 0.05% Brij 35. Gels were stained in 0.1% Colloidal Brilliant Blue (Sigma), 10% acetic acid, and 40% methanol for 2 hours and destained in 10% acetic acid and 40% methanol. Proteins having gelatinolytic activity were visualized as clear zones in an otherwise blue gel. Photographs of the gels were scanned by an imaging densitometer and quantified using the NIH Image 1.6 software program. To ensure that differences in protein amounts did not account for the differences seen, the zymographic data were normalized to the total amount of protein applied to each lane. Of note, the total amount of protein did not vary significantly from sample to sample.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Macrophages in Human Atheroma Contain PPAR{gamma}

Analysis of human carotid atheroma (n = 12) demonstrated immunoreactive PPAR{gamma} co-localizing with macrophages (Figure 1, A and C) , so identified by morphology and by staining of parallel sections with the macrophage-specific antibody anti-CD68 (data not shown). PPAR{gamma} staining was mainly localized in the macrophage-rich shoulder region of the plaque (Figure 1A) , with 35 ± 5% of this area positive for PPAR{gamma} and 54 ± 6% positive for macrophages, as determined by color image analysis. Quantification of staining in nonshoulder regions revealed a 2 ± 1% area positive for PPAR{gamma} and 8 ± 1% for macrophages. Preabsorption of anti-PPAR{gamma} antibodies with the peptide antigen abrogated staining in adjacent sections (Figure 1B) , indicating the specificity of the immunostaining. Higher-power views of PPAR{gamma}-stained plaque (indicated by the rectangle in Figure 1A ) showed staining predominantly in nuclei of macrophages (Figure 1C) . Only occasional endothelial cells or smooth muscle cells in lesions showed immunoreactive PPAR{gamma} (data not shown). Study of nonatheromatous arterial specimens (n = 6) showed scant PPAR{gamma} in nuclei of vascular smooth muscle cells (Figure 1D) .



View larger version (106K):
[in this window]
[in a new window]
 
Figure 1. Expression of PPAR{gamma} in human atherosclerotic lesions. A: Low-power view of frozen section of human carotid lesions shows immunoreactive PPAR{gamma} next to the lipid core in the shoulder region with abundant macrophages present. Similar results were seen in other atherosclerotic specimens (n = 12). B: No immunoreactive PPAR{gamma} is detectable in parallel sections stained with PPAR{gamma} antibodies preabsorbed with the immunizing peptide, indicating that staining for PPAR{gamma} in (A) and (C) is specific. Similar results were seen with immunoglobulin G controls (not shown). C: High-power view of the area indicated by the rectangle in (A) shows PPAR{gamma} staining restricted to macrophage nuclei (see quantification in Results). D: In nonatherosclerotic arteries (n = 6), little PPAR{gamma} could be detected, with scant staining in occasional vascular smooth muscle cells.

 
Cells of the Monocyte/Macrophage Lineage Express PPAR{gamma} mRNA and Protein

Freshly prepared monocytes, monocyte-derived macrophages, and PMA-treated U937 cells all contained PPAR{gamma} mRNA as detected by a 473-bp reverse transcription-polymerase chain reaction product (Figure 2A , upper panel). For the detection of PPAR{gamma} protein, we prepared separate nuclear and cytosolic fractions of the above-mentioned cells, as well as untransfected and PPAR{gamma}-transfected fibroblasts, and performed Western blot analysis. Nuclear extracts of monocytes, monocyte-derived macrophages, and differentiated U937 cells (Figure 2A , lower panel), but not cytosolic fractions (data not shown), contained PPAR{gamma} protein. The identity of this band as PPAR{gamma} was supported by its lack of cytosolic expression, its expected apparent molecular weight (55 kd), and co-migration with a signal in fibroblasts transfected with a PPAR{gamma} expression construct. Untransfected fibroblasts demonstrate no cross-reacting band of the appropriate size (Figure 2A , lower panel).



View larger version (56K):
[in this window]
[in a new window]
 
Figure 2. A: PPAR{gamma} mRNA and protein are expressed in cells of the monocyte/macrophage lineage. Upper panel: reverse transcription-polymerase chain reaction of PPAR{gamma} mRNA in freshly prepared monocytes (Mo), monocyte-derived macrophages (MØ), and PMA-differentiated U937 cells (U937) reveals a cDNA fragment of the expected size. Also shown are a 100-bp DNA ladder (MW) and negative control without cDNA (Co). Lower panel: Western blot analysis of PPAR{gamma} protein expression in nuclear extracts of freshly prepared monocytes (Mo), monocyte-derived macrophages (MØ), and U937 cells (U937) reveals a band of the appropriate size. The identity of this band is confirmed by co-migration with a band seen in PPAR{gamma}-transfected human skin fibroblasts (+) but not in similar but untransfected fibroblasts (-). All results shown were reproduced in three independent experiments. B (right): PPAR{gamma} mRNA expression in undifferentiated (Undiff.) and PMA-differentiated U937 cells (Diff.), as shown by Northern blot analysis. Differentiated U937 cells show increased PPAR{gamma} mRNA expression compared with undifferentiated cells. B (left): Ethidium bromide staining demonstrates equal loading of intact RNA. Results shown were reproduced in three independent experiments.

 
Increased PPAR{gamma} Expression during PMA-Induced Differentiation of U937 Cells

To investigate further the regulation of PPAR{gamma} during differentiation of cells of the monocytic lineage, U937 cells were stimulated with PMA (10 µg/L) for 12 hours, and Northern blotting was performed. This treatment increased PPAR{gamma} mRNA expression (Figure 2B) . Western blot analysis showed a parallel rise in protein levels in nuclear fractions of PMA-treated U937 cells (data not shown). Neither undifferentiated nor differentiated U937 cells demonstrate PPAR{gamma} in the cytosol (data not shown).

PPAR{gamma} Activators Troglitazone and PGJ2 Decrease Both Protein Levels and Gelatinolytic Activity of MMP-9 Secreted from Monocyte-Derived Macrophages

To elucidate the functional relevance of PPAR{gamma} activation, we investigated the effect of the selective PPAR{gamma} activators troglitazone and 15 d-PGJ2 on MMP-9 activity in monocyte-derived macrophages. Monocytes were cultured initially in human serum and then transferred to serum-free medium in the absence or presence of troglitazone or 15 d-PGJ2. Secreted MMP-9 gelatinolytic activity was then measured using substrate zymography. As previously reported, culture of monocytes for 6 days with human serum substantially increases gelatinolytic activity in the supernatant compared with freshly prepared monocytes (Figure 3A) . Concurrent treatment of monocytes with troglitazone or 15 d-PGJ2 in serum-free medium during this transition toward monocyte-derived macrophages inhibited the increase in gelatinolytic activity in a concentration-dependent manner (Figure 3A) . Quantification of gelatinolytic areas by densitometry revealed a reduction of MMP-9 activity after treatment with troglitazone (1 µM and 5 µM) to 73.5 ± 1.9% and 53.3 ± 12.2% (P < 0.01), respectively, and with 15 d-PGJ2 (1 µM and 5 µM) to 79.0 ± 14.6% and 45.5 ± 8.9% (P < 0.01), respectively, in both cases relative to control cells (n = 3). Similar results were seen in U937 cells (data not shown). Treatment with either troglitazone or 15 d-PGJ2 after 6 days of culture in human serum had no effect (data not shown), suggesting that PPAR{gamma} activation was required during differentiation for inhibition of MMP-9 levels/activity to occur. The identity of the observed gelatinolytic area was confirmed by the mobility of the band and co-migration with the known 92-kd gelatinolytic activity in PMA-treated human fibroblast supernatants (Figure 3A) . Treatment of monocyte-derived macrophages with either PPAR activator, troglitazone or 15 d-PGJ2, reduces supernatant MMP-9 protein levels from monocyte-derived macrophages (Figure 3B) . Co-migration with the known MMP-9 band of supernatants from PMA-stimulated vascular smooth muscle cells confirms identity of the detected band (Figure 3B) .



View larger version (42K):
[in this window]
[in a new window]
 
Figure 3. A: PPAR{gamma} activators decrease MMP-9 gelatinolytic activity in supernatants from monocyte-derived macrophages (MØ) in a concentration-dependent fashion, as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis zymography. Monocytes were cultured in 5% human serum in the presence or absence of troglitazone or 15 d-PGJ2 as indicated. Supernatants of PMA-treated fibroblasts served as a control (Co). Gelatinolytic activity of freshly prepared monocytes is also shown (Mo). Equal amounts of lysates were loaded. Results shown were reproduced in three independent experiments. B: PPAR{gamma} activators decrease MMP-9 protein levels in supernatants from monocyte-derived macrophages (MØ). Vascular smooth muscle cells treated with PMA at 50 µg/L served as a control (Co). Supernatants from freshly prepared monocyte supernatant (Mo) are also shown. Similar results were reproduced in three independent experiments.

 

    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
This study demonstrates PPAR{gamma} expression in macrophages in human atherosclerotic lesions. Furthermore, we find differentiation-dependent regulation of PPAR{gamma} expression in cells of the monocyte/macrophage lineage in vitro. Treatment of differentiated monocyte-derived macrophages in vitro with two different PPAR{gamma} activators, 15 d-PGJ2 or troglitazone, decreased both MMP-9 protein levels and MMP-9 gelatinolytic activity in a concentration-dependent manner.

Coronary atherosclerosis is typically a diffuse process.26 Nevertheless, despite systemic risk factors, such as low-density lipoprotein levels, and the presence of macrophages and inflammatory cytokines in most plaques, some arterial plaques rupture, whereas others do not. The factors accounting for this variability are unclear. Certainly, monocytes/macrophages are intimately involved in plaque rupture.2,27 As monocytes differentiate in the subintima into macrophages and foam cells, the atherogenic microenvironment influences transcriptional regulation of genes, the products of which will determine the natural history of the lesion.1 MMPs furnish one example of proteins, the induction and expression of which by monocytes/macrophages likely contributes to subsequent plaque rupture.2 Several lines of evidence indicate that lesional macrophages synthesize MMPs de novo.28,29. These proteins are enzymatically active, as shown by zymographic analysis of human arterial specimens.30 Secretion of these MMPs, with MMP-9 prominent among them, favors destabilization of the plaque's fibrous cap.1

Our findings suggest that PPAR{gamma}, as a nuclear transcription factor present in lesional macrophages, may inhibit MMP expression and activity. Furthermore, PPAR{gamma} may control expression of other target genes within the arterial wall, thus modulating a cascade of responses in monocytes/macrophages after activation by its endogenous or synthetic ligand(s).

15 d-PGJ2, a naturally occurring ligand for PPAR{gamma}, likely interacts with monocytes/macrophages. J2 prostanoids, and the immediate upstream precursors of 15 d-PGJ2, are found in vivo.31 Prostaglandins themselves are synthesized from fatty acids, with arachadonic acid as the primary source. 15 d-PGD2, the major prostaglandin in most tissues, is converted to 15 d-PGJ2.32 This process requires 15 d-PGD2 synthetase, an enzyme produced primarily by macrophages and other antigen-presenting cells.33 Thus, 15 d-PGJ2, acting through PPAR{gamma}, may be an important regulator of macrophage function. Troglitazone, a synthetic PPAR{gamma} activator, is currently in clinical use as an antidiabetic agent.34,36 The implications of its effects on inhibiting macrophage MMP-9 matrix degradation merit further consideration in a clinical context.

A very recent report showed that the PPAR{gamma} activator 15 d-PGJ2 inhibits expression of an MMP-9 promoter luciferase construct when transfected into U937 cells.25 Our findings support a critical role for PPAR{gamma} in atherosclerosis, demonstrating its presence in monocytes/macrophages of human atheroma and increased expression during differentiation in vitro. Furthermore, the present study of MMP-9 gelatinolytic activity illustrates directly the functional relevance of PPAR{gamma} in these cells. These results establish a rationale for further study of PPAR{gamma} in monocyte/macrophage biology, particularly in the context of atherosclerosis.


    Acknowledgements
 
We thank Eugenia Schvartz for her expert technical assistance and our colleagues in the Vascular Medicine and Atherosclerosis Unit for their insightful technical and intellectual advice.


    Footnotes
 
Address reprint requests to Jorge Plutzky, Vascular Medicine and Atherosclerosis Unit, Cardiovascular Division, Brigham and Women's Hospital, 221 Longwood Avenue, Boston, MA 02115. E-mail: jplutzky{at}bics.bwh.harvard.edu

Supported by Deutsche Forschungsgemeinschaft Grant MA 2047/1-1 (to NM) and National Institutes of Health Grants HL 03107 and P50HL56985 (to JP), and P50HL56985 and R37HL34636 (to PL).

Accepted for publication April 2, 1998.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Libby P, Geng Y, Aikawa M, Schoenbeck U, Mach F, Clinton S, Sukhova G, Lee R: Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol 1996, 7:330-335[Medline]
  2. Dollery C, McEwan J, Henney A: Matrix metalloproteinases and cardiovascular disease. Circ Res 1995, 77:863-868[Free Full Text]
  3. Davies M, Richardson P, Woolf N, Katz D, Mann J: Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cells content. Br Heart J 1993, 69:377-381[Abstract/Free Full Text]
  4. Lendon CL, Davies MJ, Born GV, Richardson PD: Atherosclerotic plaque caps are locally weakened when macrophages density is increased. Atherosclerosis 1991, 87:87-90[Medline]
  5. Nikkari S, O'Brien K, Ferguson M, Hatsukami T, Welgus H, Clowes A: Interstitial collagenase (MMP-1) expression in human carotid atherosclerotics. Circulation 1995, 92:1393-1398[Abstract/Free Full Text]
  6. Galis Z, Sukhova G, Lark M, Libby P: Increased expression of matrix metalloproteinases and matrix degradation activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994, 94:2493-2503
  7. Goetzl E, Banda M, Leppert D: Matrix metalloproteinases in immunity. J Immunol 1996, 156:1-4[Abstract]
  8. Welgus H, Campbell E, Cury J, Eisen A, Senior RM, Goldberg G: Neutral metalloproteinases produced by human mononuclear phagocytes: enzyme profile, regulation, and expression during cellular development. J Clin Invest 1990, 86:1496-1502
  9. Saren P, Welgus H, Kovanen P: TNF-{alpha} and IL-1ß selectively induce expression of 92-kd gelatinase by human macrophages. J Immunol 1996, 157:4159-4165[Abstract]
  10. Schoenbeck U, Mach F, Sukhova G, Murphy C, Bonnefoy J-Y, Fabunmi R, Libby P: Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes. Circ Res 1997, 81:448-454[Abstract/Free Full Text]
  11. Schroen DJ, Brinckerhoff C: Nuclear hormone receptors inhibit matrix metalloproteinases (MMP) gene expression through diverse mechanisms. Gene Exp 1996, 6:197-207
  12. Schoonjans K, Martin G, Staels B, Auwerx J: Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol 1997, 8:159-166[Medline]
  13. Vidal-Puig AJ, Considine RV, Jimenez-Linan MA, Pories WJ, Caro JF, Flier JS: Peroxisome proliferator-activated receptor gene expression in human tissues: effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997, 99:2416-2422[Medline]
  14. Tontonoz P, Hu E, Spiegelman BM: Stimulation of adipogenesis in fibroblasts by PPAR {gamma}2, a lipid-activated transcription factor. Cell 1994, 79:1147-1156[Medline]
  15. Brun R, Tontonoz P, Forman B, Ellis RJ, Evan R, Spiegelman BM: Differential activation of adipogenesis by multiple PPAR isoforms. Genes Dev 1996, 10:974-984[Abstract/Free Full Text]
  16. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans R: The nuclear receptor superfamily: the second decade. Cell 1995, 83:835-839[Medline]
  17. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans R: M. 15-Deoxy-delta 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR {gamma}. Cell 1995, 83:803-812[Medline]
  18. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris D, Lehmann JM: A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor {gamma} and promotes adipocyte differentiation. Cell 1995, 83:813-819[Medline]
  19. Yu K, Bayona W, Kallen CB, Harding HP, Ravera CP, McMahon G, Brown M, Lazar MA: Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 1995, 270:23975-23983[Abstract/Free Full Text]
  20. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor {gamma}. J Biol Chem 1995, 270:12953-12956[Abstract/Free Full Text]
  21. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM: The structure-activity relationship between peroxisome proliferator-activated receptor {gamma} agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 1996, 39:665-668[Medline]
  22. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard JM, Lehmann JM: Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors {alpha} and {gamma}. Proc Natl Acad Sci USA 1997, 94:4318-4323[Abstract/Free Full Text]
  23. Greene M, Blumberg B, McBride O, Kronquist K, Kwan K, Hsieh L, Greene G, Nimer S: Isolation of the human peroxisome proliferator activated receptor {gamma} cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expression 1995, 4:281-299[Medline]
  24. Jiang C, Ting A, Seed B: PPAR-{gamma} agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391:82-86[Medline]
  25. Ricote M, Li A, Wilson T, Kelly C, Glass C: The peroxisome proliferator-activated receptor-{gamma} is a negative regulator of macrophage activation. Nature 1998, 391:79-82[Medline]
  26. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801-809[Medline]
  27. Raines E, Ross R: Is overamplification of the normal macrophage defensive role critical to lesion development? Ann NY Acad Sci 1997, 811:76-85[Medline]
  28. Galis Z, Sukhova G, Kranzhoefer R, Clark S, Libby P: Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci USA 1995, 92:402-406[Abstract/Free Full Text]
  29. Henney A, Wakeley P, Davies M, Foster K, Hembry R, Murphy G, Humphries S: Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci USA 1991, 88:8154-8158[Abstract/Free Full Text]
  30. Galis Z, Sukhova G, Libby P: Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. FASEB J 1995, 9:974-980[Abstract]
  31. Fukushima M: Biological activities and mechanisms of action of PGJ2 and related compounds: an update. Prostaglandins Leukotrienes Essent Fatty Acids 1992, 47:1-12[Medline]
  32. Giles H, Leff P: The biology and pharmacology of PGD2. Prostaglandins 1988, 35:277-300[Medline]
  33. Urade Y, Ujihara M, Horigushi Y, Ikai K, Hayaishi O: The major source of endogenous prostaglandin D2 is likely antigen-presenting cells. J Immunol 1989, 143:2982-2989[Abstract]
  34. Nolen J, Ludvik B, Beerdsen P: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994, 331:1188-1193[Abstract/Free Full Text]
  35. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI: Efficacy and metabolic effects of merformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998, 338:867-872[Abstract/Free Full Text]
  36. Schwartz S, Raskin P, Fonseca V, Graveline JF: Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. N Engl J Med 1998, 338:861-866[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
J. Virol.Home page
B. Rauwel, B. Mariame, H. Martin, R. Nielsen, S. Allart, B. Pipy, S. Mandrup, M. D. Devignes, D. Evain-Brion, T. Fournier, et al.
Activation of Peroxisome Proliferator-Activated Receptor Gamma by Human Cytomegalovirus for De Novo Replication Impairs Migration and Invasiveness of Cytotrophoblasts from Early Placentas
J. Virol., March 15, 2010; 84(6): 2946 - 2954.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
F.-I Hsieh, W.-C. Lo, H.-J. Lin, Y.-C. Hsieh, L.-M. Lien, C.-H. Bai, H.-P. Tseng, and H.-Y. Chiou
Significant Synergistic Effect of Peroxisome Proliferator-Activated Receptor {gamma} C-2821T and Diabetes on the Risk of Ischemic Stroke
Diabetes Care, November 1, 2009; 32(11): 2033 - 2035.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Jones, R. Deb, E. Torsney, F. Howe, M. Dunkley, Y. Gnaneswaran, D. Gaze, H. Nasr, I. M. Loftus, M. M. Thompson, et al.
Rosiglitazone Reduces the Development and Rupture of Experimental Aortic Aneurysms
Circulation, June 23, 2009; 119(24): 3125 - 3132.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
C.-S. Lee, Y.-W. Kwon, H.-M. Yang, S.-H. Kim, T.-Y. Kim, J. Hur, K.-W. Park, H.-J. Cho, H.-J. Kang, Y.-B. Park, et al.
New Mechanism of Rosiglitazone to Reduce Neointimal Hyperplasia: Activation of Glycogen Synthase Kinase-3{beta} Followed by Inhibition of MMP-9
Arterioscler Thromb Vasc Biol, April 1, 2009; 29(4): 472 - 479.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. C. Newby
Metalloproteinase Expression in Monocytes and Macrophages and its Relationship to Atherosclerotic Plaque Instability
Arterioscler Thromb Vasc Biol, December 1, 2008; 28(12): 2108 - 2114.
[Abstract] [Full Text] [PDF]


Home page
Ther Adv Cardiovasc DisHome page
M. Collino, N. S.A. Patel, and C. Thiemermann
Review: PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury
Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 179 - 197.
[Abstract] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
E. Rigamonti, G. Chinetti-Gbaguidi, and B. Staels
Regulation of Macrophage Functions by PPAR-{alpha}, PPAR-{gamma}, and LXRs in Mice and Men
Arterioscler Thromb Vasc Biol, June 1, 2008; 28(6): 1050 - 1059.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
E. Rigamonti, C. Fontaine, B. Lefebvre, C. Duhem, P. Lefebvre, N. Marx, B. Staels, and G. Chinetti-Gbaguidi
Induction of CXCR2 Receptor by Peroxisome Proliferator-Activated Receptor {gamma} in Human Macrophages
Arterioscler Thromb Vasc Biol, May 1, 2008; 28(5): 932 - 939.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
S. Z. Duan, M. G. Usher, and R. M. Mortensen
Peroxisome Proliferator-Activated Receptor-{gamma}-Mediated Effects in the Vasculature
Circ. Res., February 15, 2008; 102(3): 283 - 294.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. K. McGuire and S. E. Inzucchi
New Drugs for the Treatment of Diabetes Mellitus: Part I: Thiazolidinediones and Their Evolving Cardiovascular Implications
Circulation, January 22, 2008; 117(3): 440 - 449.
[Full Text] [PDF]


Home page
Vasc MedHome page
A. S. Kelly, A. M. Thelen, D. R. Kaiser, J. M. Gonzalez-Campoy, and A. J. Bank
Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus
Vascular Medicine, November 1, 2007; 12(4): 311 - 318.
[Abstract] [PDF]


Home page
Ther Adv Cardiovasc DisHome page
C. Schindler
Review: The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis?
Therapeutic Advances in Cardiovascular Disease, October 1, 2007; 1(1): 7 - 26.
[Abstract] [PDF]


Home page
CirculationHome page
J. D. Brown and J. Plutzky
Peroxisome Proliferator Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets
Circulation, January 30, 2007; 115(4): 518 - 533.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
F. Demirturk, H. Aytan, A. Caliskan, P. Aytan, T. Yener, D. Koseoglu, and A. Yenisehirli
The effect of rosiglitazone in the prevention of intra-abdominal adhesion formation in a rat uterine horn model
Hum. Reprod., November 1, 2006; 21(11): 3008 - 3013.
[Abstract] [Full Text] [PDF]


Home page
Diabetes and Vascular Disease ResearchHome page
C. B Patle, J. A De Lemos, K. L Wyne, and D. K McGuire
Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPAR{gamma} agonism
Diabetes and Vascular Disease Research, September 1, 2006; 3(2): 65 - 71.
[Abstract] [PDF]


Home page
Diabetes CareHome page
Z. T. Bloomgarden
Third Annual World Congress on the Insulin Resistance Syndrome: Atherothrombotic disease
Diabetes Care, August 1, 2006; 29(8): 1973 - 1980.
[Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
K. Wang, Z. Zhou, M. Zhang, L. Fan, F. Forudi, X. Zhou, W. Qu, A. M. Lincoff, A. M. Schmidt, E. J. Topol, et al.
Peroxisome Proliferator-Activated Receptor {gamma} Down-Regulates Receptor for Advanced Glycation End Products and Inhibits Smooth Muscle Cell Proliferation in a Diabetic and Nondiabetic Rat Carotid Artery Injury Model
J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 37 - 43.
[Abstract] [Full Text] [PDF]


Home page
ReproductionHome page
J. Banerjee and C. M Komar
Effects of luteinizing hormone on peroxisome proliferator-activated receptor {gamma} in the rat ovary before and after the gonadotropin surge
Reproduction, January 1, 2006; 131(1): 93 - 101.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
S Soumian, R Gibbs, A Davies, and C Albrecht
mRNA expression of genes involved in lipid efflux and matrix degradation in occlusive and ectatic atherosclerotic disease
J. Clin. Pathol., December 1, 2005; 58(12): 1255 - 1260.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Xia, M. Hou, H. Zhu, J. Ma, Z. Tang, Q. Wang, Y. Li, D. Chi, X. Yu, T. Zhao, et al.
Anthocyanins Induce Cholesterol Efflux from Mouse Peritoneal Macrophages: THE ROLE OF THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR {gamma}-LIVER X RECEPTOR {alpha}-ABCA1 PATHWAY
J. Biol. Chem., November 4, 2005; 280(44): 36792 - 36801.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
S. H. Han, M. J. Quon, and K. K. Koh
Beneficial Vascular and Metabolic Effects of Peroxisome Proliferator-Activated Receptor-{alpha} Activators
Hypertension, November 1, 2005; 46(5): 1086 - 1092.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. Klotz, M. Schmidt, T. Giese, M. Sastre, P. Knolle, T. Klockgether, and M. T. Heneka
Proinflammatory Stimulation and Pioglitazone Treatment Regulate Peroxisome Proliferator-Activated Receptor {gamma} Levels in Peripheral Blood Mononuclear Cells from Healthy Controls and Multiple Sclerosis Patients
J. Immunol., October 15, 2005; 175(8): 4948 - 4955.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
T. J. Standiford, V. G. Keshamouni, and R. C. Reddy
Peroxisome Proliferator-activated Receptor-{gamma} as a Regulator of Lung Inflammation and Repair
Proceedings of the ATS, October 1, 2005; 2(3): 226 - 231.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
N. Hennuyer, A. Tailleux, G. Torpier, H. Mezdour, J.-C. Fruchart, B. Staels, and C. Fievet
PPAR{alpha}, but not PPAR{gamma}, Activators Decrease Macrophage-Laden Atherosclerotic Lesions in a Nondiabetic Mouse Model of Mixed Dyslipidemia
Arterioscler Thromb Vasc Biol, September 1, 2005; 25(9): 1897 - 1902.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. Pfutzner, N. Marx, G. Lubben, M. Langenfeld, D. Walcher, T. Konrad, and T. Forst
Improvement of Cardiovascular Risk Markers by Pioglitazone Is Independent From Glycemic Control: Results From the Pioneer Study
J. Am. Coll. Cardiol., June 21, 2005; 45(12): 1925 - 1931.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
S Soumian, C Albrecht, A. Davies, and R. Gibbs
ABCA1 and atherosclerosis
Vascular Medicine, May 1, 2005; 10(2): 109 - 119.
[Abstract] [PDF]


Home page
ANGIOLOGYHome page
N. P. Kadoglou, S. S. Daskalopoulou, D. Perrea, and C. D. Liapis
Matrix Metalloproteinases and Diabetic Vascular Complications
Angiology, March 1, 2005; 56(2): 173 - 189.
[Abstract] [PDF]


Home page
Cardiovasc ResHome page
M. Abdelrahman, A. Sivarajah, and C. Thiemermann
Beneficial effects of PPAR-{gamma} ligands in ischemia-reperfusion injury, inflammation and shock
Cardiovasc Res, March 1, 2005; 65(4): 772 - 781.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. J. Scotton, F. O. Martinez, M. J. Smelt, M. Sironi, M. Locati, A. Mantovani, and S. Sozzani
Transcriptional Profiling Reveals Complex Regulation of the Monocyte IL-1{beta} System by IL-13
J. Immunol., January 15, 2005; 174(2): 834 - 845.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
S. C. Tyagi, W. Rodriguez, A. M. Patel, A. M. Roberts, J. C. Falcone, J. C. Passmore, J. T. Fleming, and I. G. Joshua
Hyperhomocysteinemic Diabetic Cardiomyopathy: Oxidative Stress, Remodeling, and Endothelial-Myocyte Uncoupling
Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2005; 10(1): 1 - 10.
[Abstract] [PDF]


Home page
Physiol. Rev.Home page
A. C. Newby
Dual Role of Matrix Metalloproteinases (Matrixins) in Intimal Thickening and Atherosclerotic Plaque Rupture
Physiol Rev, January 1, 2005; 85(1): 1 - 31.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Giri, R. Rattan, A. K. Singh, and I. Singh
The 15-Deoxy-{delta}12,14-Prostaglandin J2 Inhibits the Inflammatory Response in Primary Rat Astrocytes via Down-Regulating Multiple Steps in Phosphatidylinositol 3-Kinase-Akt-NF-{kappa}B-p300 Pathway Independent of Peroxisome Proliferator-Activated Receptor {gamma}
J. Immunol., October 15, 2004; 173(8): 5196 - 5208.
[Abstract] [Full Text] [PDF]


Home page
Diabetes and Vascular Disease ResearchHome page
D. Walcher and N. Marx
Insulin resistance and cardiovascular disease: the role of PPAR{gamma} activators beyond their anti-diabetic action
Diabetes and Vascular Disease Research, October 1, 2004; 1(2): 76 - 81.
[Abstract] [PDF]


Home page
Am. J. Pathol.Home page
X. Wang, J. Liang, T. Koike, H. Sun, T. Ichikawa, S. Kitajima, M. Morimoto, H. Shikama, T. Watanabe, Y. Sasaguri, et al.
Overexpression of Human Matrix Metalloproteinase-12 Enhances the Development of Inflammatory Arthritis in Transgenic Rabbits
Am. J. Pathol., October 1, 2004; 165(4): 1375 - 1383.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Francois, P. Richette, L. Tsagris, M. Raymondjean, M.-C. Fulchignoni-Lataud, C. Forest, J.-F. Savouret, and M.-T. Corvol
Peroxisome Proliferator-activated Receptor-{gamma} Down-regulates Chondrocyte Matrix Metalloproteinase-1 via a Novel Composite Element
J. Biol. Chem., July 2, 2004; 279(27): 28411 - 28418.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
M.A. Birrell, H.J. Patel, K. McCluskie, S. Wong, T. Leonard, M.H. Yacoub, and M.G. Belvisi
PPAR-{gamma} agonists as therapy for diseases involving airway neutrophilia
Eur. Respir. J., July 1, 2004; 24(1): 18 - 23.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
G. Reiterer, M. Toborek, and B. Hennig
Peroxisome Proliferator Activated Receptors {alpha} and {gamma} Require Zinc for Their Anti-inflammatory Properties in Porcine Vascular Endothelial Cells
J. Nutr., July 1, 2004; 134(7): 1711 - 1715.
[Abstract] [Full Text]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
K. S. Meir and E. Leitersdorf
Atherosclerosis in the Apolipoprotein E-Deficient Mouse: A Decade of Progress
Arterioscler Thromb Vasc Biol, June 1, 2004; 24(6): 1006 - 1014.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
N. Marx, H. Duez, J.-C. Fruchart, and B. Staels
Peroxisome Proliferator-Activated Receptors and Atherogenesis: Regulators of Gene Expression in Vascular Cells
Circ. Res., May 14, 2004; 94(9): 1168 - 1178.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. P. Kumar, F. J. Piedrafita, and W. F. Reynolds
Peroxisome Proliferator-activated Receptor {gamma} Ligands Regulate Myeloperoxidase Expression in Macrophages by an Estrogen-dependent Mechanism Involving the -463GA Promoter Polymorphism
J. Biol. Chem., February 27, 2004; 279(9): 8300 - 8315.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. Corti, J. I. Osende, J. T. Fallon, V. Fuster, G. Mizsei, H. Jneid, S. D. Wright, W. F. Chaplin, and J. J. Badimon
The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging
J. Am. Coll. Cardiol., February 4, 2004; 43(3): 464 - 473.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
W. A. Hsueh and D. Bruemmer
Peroxisome Proliferator-Activated Receptor {gamma}: Implications for Cardiovascular Disease
Hypertension, February 1, 2004; 43(2): 297 - 305.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
H. Hammad, H. J. de Heer, T. Soullie, V. Angeli, F. Trottein, H. C. Hoogsteden, and B. N. Lambrecht
Activation of Peroxisome Proliferator-Activated Receptor-{gamma} in Dendritic Cells Inhibits the Development of Eosinophilic Airway Inflammation in a Mouse Model of Asthma
Am. J. Pathol., January 1, 2004; 164(1): 263 - 271.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
H. Du, S. Schiavi, N. Wan, M. Levine, D. P. Witte, and G. A. Grabowski
Reduction of Atherosclerotic Plaques by Lysosomal Acid Lipase Supplementation
Arterioscler Thromb Vasc Biol, January 1, 2004; 24(1): 147 - 154.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. R. Worley, M. D. Baugh, D. A. Hughes, D. R. Edwards, A. Hogan, M. J. Sampson, and J. Gavrilovic
Metalloproteinase Expression in PMA-stimulated THP-1 Cells: EFFECTS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-{gamma} (PPAR{gamma}) AGONISTS AND 9-CIS-RETINOIC ACID
J. Biol. Chem., December 19, 2003; 278(51): 51340 - 51346.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. S. Sidhu, D. Cowan, and J.-C. Kaski
The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients
J. Am. Coll. Cardiol., November 19, 2003; 42(10): 1757 - 1763.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
B. OSTERUD and E. BJORKLID
Role of Monocytes in Atherogenesis
Physiol Rev, October 1, 2003; 83(4): 1069 - 1112.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. F. Luscher, M. A. Creager, J. A. Beckman, and F. Cosentino
Diabetes and Vascular Disease: Pathophysiology, Clinical Consequences, and Medical Therapy: Part II
Circulation, September 30, 2003; 108(13): 1655 - 1661.
[Full Text] [PDF]


Home page
ThoraxHome page
M Hetzel, D Walcher, M Grub, H Bach, V Hombach, and N Marx
Inhibition of MMP-9 expression by PPAR{gamma} activators in human bronchial epithelial cells
Thorax, September 1, 2003; 58(9): 778 - 783.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
F. Liang, F. Wang, S. Zhang, and D. G. Gardner
Peroxisome Proliferator Activated Receptor (PPAR){alpha} Agonists Inhibit Hypertrophy of Neonatal Rat Cardiac Myocytes
Endocrinology, September 1, 2003; 144(9): 4187 - 4194.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Taba, M. Miyagi, Y. Miwa, H. Inoue, F. Takahashi-Yanaga, S. Morimoto, and T. Sasaguri
15-Deoxy-{Delta}12,14-prostaglandin J2 and laminar fluid shear stress stabilize c-IAP1 in vascular endothelial cells
Am J Physiol Heart Circ Physiol, June 5, 2003; 285(1): H38 - H46.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
N. Varo, D. Vicent, P. Libby, R. Nuzzo, A. L. Calle-Pascual, M. R. Bernal, A. Fernandez-Cruz, A. Veves, P. Jarolim, J. J. Varo, et al.
Elevated Plasma Levels of the Atherogenic Mediator Soluble CD40 Ligand in Diabetic Patients: A Novel Target of Thiazolidinediones
Circulation, June 3, 2003; 107(21): 2664 - 2669.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Gurnell, D. B. Savage, V. K. K. Chatterjee, and S. O'Rahilly
The Metabolic Syndrome: Peroxisome Proliferator-Activated Receptor {gamma} and Its Therapeutic Modulation
J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2412 - 2421.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
G. Haraguchi, Y. Kobayashi, M. L. Brown, A. Tanaka, M. Isobe, S. H. Gianturco, and W. A. Bradley
PPAR{alpha} and PPAR{gamma} activators suppress the monocyte-macrophage apoB-48 receptor
J. Lipid Res., June 1, 2003; 44(6): 1224 - 1231.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
V. Angeli, H. Hammad, B. Staels, M. Capron, B. N. Lambrecht, and F. Trottein
Peroxisome Proliferator-Activated Receptor {gamma} Inhibits the Migration of Dendritic Cells: Consequences for the Immune Response
J. Immunol., May 15, 2003; 170(10): 5295 - 5301.
[Abstract] [Full Text] [PDF]


Home page
Diabetes Spectr.Home page
V. R. Aroda and R. R. Henry
Thiazolidinediones: Potential Link Between Insulin Resistance and Cardiovascular Disease
Diabetes Spectr, April 1, 2003; 16(2): 120 - 125.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
F. Zangeneh, Y. C. Kudva, and A. Basu
Insulin Sensitizers
Mayo Clin. Proc., April 1, 2003; 78(4): 471 - 479.
[Abstract] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
C.A. Argmann, C.G. Sawyez, C.J. McNeil, R.A. Hegele, and M.W. Huff
Activation of Peroxisome Proliferator-Activated Receptor Gamma and Retinoid X Receptor Results in Net Depletion of Cellular Cholesteryl Esters in Macrophages Exposed to Oxidized Lipoproteins
Arterioscler Thromb Vasc Biol, March 1, 2003; 23(3): 475 - 482.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
N. Marx, J. Froehlich, L. Siam, J. Ittner, G. Wierse, A. Schmidt, H. Scharnagl, V. Hombach, and W. Koenig
Antidiabetic PPAR{gamma}-Activator Rosiglitazone Reduces MMP-9 Serum Levels in Type 2 Diabetic Patients With Coronary Artery Disease
Arterioscler Thromb Vasc Biol, February 1, 2003; 23(2): 283 - 288.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
H. S. Sood, M. J. Hunt, and S. C. Tyagi
Peroxisome proliferator ameliorates endothelial dysfunction in a murine model of hyperhomocysteinemia
Am J Physiol Lung Cell Mol Physiol, February 1, 2003; 284(2): L333 - L341.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. Pang, M. Nie, L. Corbett, and A. J. Knox
Cyclooxygenase-2 Expression by Nonsteroidal Anti-inflammatory Drugs in Human Airway Smooth Muscle Cells: Role of Peroxisome Proliferator-Activated Receptors
J. Immunol., January 15, 2003; 170(2): 1043 - 1051.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
C. Kluft, R. Kleemann, and M.P.M. de Maat
How best to counteract the enemies? By controlling inflammation in the coronary circulation
Eur. Heart J. Suppl., November 1, 2002; 4(suppl_G): G53 - G65.
[Abstract] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
M. J. Hunt and S. C. Tyagi
Peroxisome proliferators compete and ameliorate Hcy-mediated endocardial endothelial cell activation
Am J Physiol Cell Physiol, October 1, 2002; 283(4): C1073 - C1079.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
Y. Takata, Y. Kitami, Z.-H. Yang, M. Nakamura, T. Okura, and K. Hiwada
Vascular Inflammation Is Negatively Autoregulated by Interaction Between CCAAT/Enhancer-Binding Protein-{delta} and Peroxisome Proliferator-Activated Receptor-{gamma}
Circ. Res., September 6, 2002; 91(5): 427 - 433.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
R. Yamazaki, N. Kusunoki, T. Matsuzaki, S. Hashimoto, and S. Kawai
Nonsteroidal Anti-Inflammatory Drugs Induce Apoptosis in Association with Activation of Peroxisome Proliferator-Activated Receptor gamma in Rheumatoid Synovial Cells
J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 18 - 25.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
C. S. Elangbam, T. A. Brodie, H. Roger Brown, J. B. Nold, T. J. Raczniak, R. D. Tyler, R. M. Lightfoot, and H. G. Wall
Vascular Effects of GI262570X (PPAR-{gamma} agonist) in the Brown Adipose Tissue of Han Wistar Rats: A Review of 1-month, 13-week, 27-week and 2-year Oral Toxicity Studies
Toxicol Pathol, June 1, 2002; 30(4): 420 - 426.
[Abstract] [PDF]


Home page
JAMAHome page
J. A. Beckman, M. A. Creager, and P. Libby
Diabetes and Atherosclerosis: Epidemiology, Pathophysiology, and Management
JAMA, May 15, 2002; 287(19): 2570 - 2581.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
F. Bureau, C. Desmet, D. Melotte, F. Jaspar, C. Volanti, A. Vanderplasschen, P.-P. Pastoret, J. Piette, and P. Lekeux
A Proinflammatory Role for the Cyclopentenone Prostaglandins at Low Micromolar Concentrations: Oxidative Stress-Induced Extracellular Signal-Regulated Kinase Activation Without NF-{kappa}B Inhibition
J. Immunol., May 15, 2002; 168(10): 5318 - 5325.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
Q. N. Diep, M. El Mabrouk, J. S. Cohn, D. Endemann, F. Amiri, A. Virdis, M. F. Neves, and E. L. Schiffrin
Structure, Endothelial Function, Cell Growth, and Inflammation in Blood Vessels of Angiotensin II-Infused Rats: Role of Peroxisome Proliferator-Activated Receptor-{gamma}
Circulation, May 14, 2002; 105(19): 2296 - 2302.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. Cuzzocrea, N. S. Wayman, E. Mazzon, L. Dugo, R. Di Paola, I. Serraino, D. Britti, P. K. Chatterjee, A. P. Caputi, and C. Thiemermann
The Cyclopentenone Prostaglandin 15-Deoxy-Delta 12,14-Prostaglandin J2 Attenuates the Development of Acute and Chronic Inflammation
Mol. Pharmacol., May 1, 2002; 61(5): 997 - 1007.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
O. Barbier, I. P. Torra, Y. Duguay, C. Blanquart, J.-C. Fruchart, C. Glineur, and B. Staels
Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors in Lipid Metabolism and Atherosclerosis
Arterioscler Thromb Vasc Biol, May 1, 2002; 22(5): 717 - 726.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
C. M. Komar and T. E. Curry Jr
Localization and Expression of Messenger RNAs for the Peroxisome Proliferator-Activated Receptors in Ovarian Tissue from Naturally Cycling and Pseudopregnant Rats
Biol Reprod, May 1, 2002; 66(5): 1531 - 1539.
[Abstract] [Full Text]


Home page
Mol. Cell. Biol.Home page
T. E. Akiyama, S. Sakai, G. Lambert, C. J. Nicol, K. Matsusue, S. Pimprale, Y.-H. Lee, M. Ricote, C. K. Glass, H. B. Brewer Jr., et al.
Conditional Disruption of the Peroxisome Proliferator-Activated Receptor {gamma} Gene in Mice Results in Lowered Expression of ABCA1, ABCG1, and apoE in Macrophages and Reduced Cholesterol Efflux
Mol. Cell. Biol., April 15, 2002; 22(8): 2607 - 2619.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. V. Pontsler, A. St. Hilaire, G. K. Marathe, G. A. Zimmerman, and T. M. McIntyre
Cyclooxygenase-2 Is Induced in Monocytes by Peroxisome Proliferator Activated Receptor gamma and Oxidized Alkyl Phospholipids from Oxidized Low Density Lipoprotein
J. Biol. Chem., April 5, 2002; 277(15): 13029 - 13036.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
N. Marx, B. Kehrle, K. Kohlhammer, M. Grub, W. Koenig, V. Hombach, P. Libby, and J. Plutzky
PPAR Activators as Antiinflammatory Mediators in Human T Lymphocytes: Implications for Atherosclerosis and Transplantation-Associated Arteriosclerosis
Circ. Res., April 5, 2002; 90(6): 703 - 710.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. L. Schild, W. T. Schaiff, M. G. Carlson, E. J. Cronbach, D. M. Nelson, and Y. Sadovsky
The Activity of PPAR{gamma} in Primary Human Trophoblasts Is Enhanced by Oxidized Lipids
J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1105 - 1110.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
R. B. Clark
The role of PPARs in inflammation and immunity
J. Leukoc. Biol., March 1, 2002; 71(3): 388 - 400.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
Y. Oyama, N. Akuzawa, R. Nagai, and M. Kurabayashi
PPAR{gamma} Ligand Inhibits Osteopontin Gene Expression Through Interference With Binding of Nuclear Factors to A/T-Rich Sequence in THP-1 Cells
Circ. Res., February 22, 2002; 90(3): 348 - 355.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
B. R. Kwak, S. Myit, F. Mulhaupt, N. Veillard, N. Rufer, E. Roosnek, and F. Mach
PPAR{gamma} but not PPAR{alpha} Ligands Are Potent Repressors of Major Histocompatibility Complex Class II Induction in Atheroma-Associated Cells
Circ. Res., February 22, 2002; 90(3): 356 - 362.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
D J Grainger and H W L Bethell
High titres of serum antinuclear antibodies, mostly directed against nucleolar antigens, are associated with the presence of coronary atherosclerosis
Ann Rheum Dis, February 1, 2002; 61(2): 110 - 114.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
W. A. Hsueh and R. E. Law
PPAR{gamma} and Atherosclerosis: Effects on Cell Growth and Movement
Arterioscler Thromb Vasc Biol, December 1, 2001; 21(12): 1891 - 1895.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
C. M. Komar, O. Braissant, W. Wahli, and T. E. Curry Jr.
Expression and Localization of PPARs in the Rat Ovary During Follicular Development and the Periovulatory Period
Endocrinology, November 1, 2001; 142(11): 4831 - 4838.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
L. BENAYOUN, S. LETUVE, A. DRUILHE, J. BOCZKOWSKI, M.-C. DOMBRET, P. MECHIGHEL, J. MEGRET, G. LESECHE, M. AUBIER, and M. PRETOLANI
Regulation of Peroxisome Proliferator-activated Receptor gamma Expression in Human Asthmatic Airways . Relationship with Proliferation, Apoptosis, and Airway Remodeling
Am. J. Respir. Crit. Care Med., October 15, 2001; 164(8): 1487 - 1494.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
J S Sidhu and J C Kaski
Peroxisome proliferator activated receptor {gamma}: a potential therapeutic target in the management of ischaemic heart disease
Heart, September 1, 2001; 86(3): 255 - 258.
[Full Text] [PDF]


Home page
CirculationHome page
P. Libby
Current Concepts of the Pathogenesis of the Acute Coronary Syndromes
Circulation, July 17, 2001; 104(3): 365 - 372.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Aljada, H. Ghanim, J. Friedman, R. Garg, P. Mohanty, and P. Dandona
Troglitazone Reduces the Expression of PPAR{{gamma}} While Stimulating That of PPAR{{alpha}} in Mononuclear Cells in Obese Subjects
J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3130 - 3133.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
A. Tedgui and Z. Mallat
Anti-Inflammatory Mechanisms in the Vascular Wall
Circ. Res., May 11, 2001; 88(9): 877 - 887.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
H. Ghanim, R. Garg, A. Aljada, P. Mohanty, Y. Kumbkarni, E. Assian, W. Hamouda, and P. Dandona
Suppression of Nuclear Factor-{{kappa}}B and Stimulation of Inhibitor {{kappa}}B by Troglitazone: Evidence for an Anti-inflammatory Effect and a Potential Antiatherosclerotic Effect in the Obese
J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1306 - 1312.
[Abstract] [Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
T. Claudel, M. D. Leibowitz, C. Fievet, A. Tailleux, B. Wagner, J. J. Repa, G. Torpier, J.-M. Lobaccaro, J. R. Paterniti, D. J. Mangelsdorf, et al.
Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor
PNAS, February 15, 2001; (2001) 41609298.
[Abstract] [Full Text]


Home page
Diabetes CareHome page
W. A. Hsueh, S. Jackson, and R. E. Law
Control of Vascular Cell Proliferation and Migration by PPAR-{gamma}: A new approach to the macrovascular complications of diabetes
Diabetes Care, February 1, 2001; 24(2): 392 - 397.
[Abstract] [Full Text]


Home page
CirculationHome page
N. Marx, N. Mackman, U. Schonbeck, N. Yilmaz, V. Hombach, P. Libby, and J. Plutzky
PPAR{{alpha}} Activators Inhibit Tissue Factor Expression and Activity in Human Monocytes
Circulation, January 16, 2001; 103(2): 213 - 219.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
A. A. Parulkar, M. L. Pendergrass, R. Granda-Ayala, T. R. Lee, and V. A. Fonseca
Nonhypoglycemic Effects of Thiazolidinediones
Ann Intern Med, January 2, 2001; 134(1): 61 - 71.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
T. Murata, S. He, M. Hangai, T. Ishibashi, X.-P. Xi, S. Kim, W. A. Hsueh, S. J. Ryan, R. E. Law, and D. R. Hinton
Peroxisome Proliferator-Activated Receptor-{gamma} Ligands Inhibit Choroidal Neovascularization
Invest. Ophthalmol. Vis. Sci., July 1, 2000; 41(8): 2309 - 2317.
[Abstract] [Full Text]


Home page
J. Immunol.Home page
N. Marx, F. Mach, A. Sauty, J. H. Leung, M. N. Sarafi, R. M. Ransohoff, P. Libby, J. Plutzky, and A. D. Luster
Peroxisome Proliferator-Activated Receptor-{gamma} Activators Inhibit IFN-{gamma}-Induced Expression of the T Cell-Active CXC Chemokines IP-10, Mig, and I-TAC in Human Endothelial Cells
J. Immunol., June 15, 2000; 164(12): 6503 - 6508.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
U. Ikeda, M. Shimpo, Y. Murakami, and K. Shimada
Peroxisome Proliferator-Activated Receptor-{gamma} Ligands Inhibit Nitric Oxide Synthesis in Vascular Smooth Muscle Cells
Hypertension, June 1, 2000; 35(6): 1232 - 1236.
[Abstract] [Full Text] [PDF]


Home page
J. Histochem. Cytochem.Home page
C. Huin, L. Corriveau, A. Bianchi, J. M. Keller, P. Collet, P. Kremarik-Bouillaud, L. Domenjoud, P. Becuwe, H. Schohn, D. Menard, et al.
Differential Expression of Peroxisome Proliferator-activated Receptors (PPARs) in the Developing Human Fetal Digestive Tract
J. Histochem. Cytochem., May 1, 2000; 48(5): 603 - 612.
[Abstract] [Full Text]


Home page
CirculationHome page
R. E. Law, S. Goetze, X.-P. Xi, S. Jackson, Y. Kawano, L. Demer, M. C. Fishbein, W. P. Meehan, and W. A. Hsueh
Expression and Function of PPAR{gamma} in Rat and Human Vascular Smooth Muscle Cells
Circulation, March 21, 2000; 101(11): 1311 - 1318.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
A. Castrillo, M. J. M. Diaz-Guerra, S. Hortelano, P. Martin-Sanz, and L. Bosca
Inhibition of Ikappa B Kinase and Ikappa B Phosphorylation by 15-Deoxy-Delta 12,14-Prostaglandin J2 in Activated Murine Macrophages
Mol. Cell. Biol., March 1, 2000; 20(5): 1692 - 1698.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. Thieringer, J. E. Fenyk-Melody, C. B. Le Grand, B. A. Shelton, P. A. Detmers, E. P. Somers, L. Carbin, D. E. Moller, S. D. Wright, and J. Berger
Activation of Peroxisome Proliferator-Activated Receptor {gamma} Does Not Inhibit IL-6 or TNF-{alpha} Responses of Macrophages to Lipopolysaccharide In Vitro or In Vivo
J. Immunol., January 15, 2000; 164(2): 1046 - 1054.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marx, N.
Right arrow Articles by Plutzky, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marx, N.
Right arrow Articles by Plutzky, J.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS